Moxifloxacin is under clinical development by Laboratorios Sophia and currently in Phase I for Bacterial Conjunctivitis. According to GlobalData, Phase I drugs for Bacterial Conjunctivitis have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Moxifloxacin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Moxifloxacin overview

Moxifloxacin (PRO-231) is under development for the treatment of bacterial conjunctivitis. It is administered through ophthalmic route. The drug candidate acts by targeting DNA gyrase and topoisomerase IV.

Laboratorios Sophia overview

Laboratorios Sophia (Sophia Lab) is a research laboratory that develops and markets ophthalmic products. The laboratory’s products portfolio comprises antibiotics, antiallergics, steroidal and non-steroidal anti-inflammatory drugs, antiglaucoma drugs, artificial tears, controlled release devices, and viscoelastic. It operates support systems to ensure that all services meet the recognized pharmacopoeial requirements. Sophia Lab conducts research and development to advance its products. The laboratory also invests resource in training and learning programs that integrate investments in capital, products and human resources. It operates in Mexico, Panama, Colombia, Ecuador, Chile, Uruguay, and the US. Sophia Lab is headquartered in Zapopan, Jalisco, Mexico.

For a complete picture of Moxifloxacin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.